Abstract
Objective:To investigate the clinical efficacy of paroxetine combined with olanzapine in the treatment of senile schizophrenia with depression.Methods:Eighty-four elderly schizophrenic patients with depression who were admitted to our hospital from August 2016 to February 2018 were selected as research subjects and randomly divided into observation group and control group using random number table, 42 cases in each group. The control group was treated with olanzapine orally, while the observation group was treated with olanzapine and paroxetine orally. The level of homocysteine (Hcy) in the two groups was analyzed before and after treatment. The efficacy was evaluated by the Positive and Negative Symptoms Scale (PANSS) score and Hamilton Depression Scale (HAMD) score. The adverse reactions of the two groups were compared.Results:After treatment, the level of serum Hcy in the observation group was significantly lower than that in the control group (P<0.05), and it was close to the normal level. There was no significant difference in PANSS score between the two groups before treatment (P>0.05). After treatment, the negative factor score and PANSS score in the observation group were significantly lower than those in the control group, and the differences were statistically significant (P<0.05). The HAMD score of the two groups had no significant difference before treatment (P>0.05). After treatment, the HAMD score of the observation group was significantly lower than that of the control group (P<0.05). The difference of incidence of adverse reactions between the two groups had no statistical significance (P>0.05).Conclusion:Paroxetine combined with olanzapine has a definite clinical effect in the treatment of senile schizophrenia with depression. It can effectively reduce the level of serum Hcy, relieve the symptoms of schizophrenia, and alleviate the depressive symptoms of patients, with high safety. It is worth promoting.
Highlights
Schizophrenia is one of the common psychiatric diseases in clinic
The level of Hcy in the two groups decreased significantly, and the level of serum Hcy in the observation group was lower than that in the control group, and close to the normal level; there was a significant difference between the two groups (P
The results of the present study showed that the scores of negative factor, Positive and Negative Symptoms Scale (PANSS) and Hamilton Depression Scale (HAMD) of the observation group decreased after treatment and were significantly better than those of the control group, indicating that olanzapine combined with paroxetine could effectively improve the therapeutic effect in the treatment of schizophrenia and play a coordinated role, which was similar to the results of Reavley et al.[21]
Summary
Schizophrenia is one of the common psychiatric diseases in clinic. It has extremely complex pathogenesis, and its onset is slow or subacute. It has various clinical manifestations, mainly including cognition impairment and affective thinking disorder, which will severely affect the physical and psychological health of patients and their family members.[1] It is reported that 20% ~ 70% of patients with schizophrenia will have depression symptom, which will affect the treatment, and increases risks of accidents such as selfmutilation and suicide.[2] It is generally considered that depression has been one of the most important. How to treat psychiatric diseases and prevent its recurrence is an important issue that puzzles psychiatric clinicians
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
